Ipi-bev treatment, however, decreased tumor vascular ANGPT2 expression in a subset of patients, together with a decreased CD68+ and CD163+ macrophage infiltration, suggesting that ANGPT2 might have a role in resistance to ICI through TAM recruitment and that Bevacizumab might influence myeloid infiltration also by acting on the ANGPT2 levels. This evidence concerns the gene CD163 and neoplasm.